SMAD2 and myeloid sarcoma: Perturbation of SMAD2-STAT3 binding by inhibiting the palmitoylation-depalmitoylation cycle suppressed TH17 cell differentiation and reduced disease severity in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS).